Home > Healthcare > Medical Services > Gene Therapy Clinical Trial Services Market

Gene Therapy Clinical Trial Services Market Share

Report ID: GMI9312
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

Gene Therapy Clinical Trial Services Market Share

The gene therapy clinical trial services industry is characterized by rapid growth and innovation, driven by increasing investment in R&D, rising prevalence of genetic disorders, and advancements in biotechnology. Major service providers focus on offering a range of services such as regulatory consulting, patient recruitment, and data management. Additionally, collaborations between industry and academia, along with supportive regulatory frameworks, contribute to a dynamic market landscape with significant opportunities for growth and advancement in gene therapy treatments.

Gene Therapy Clinical Trial Services Market Companies

Some of the prominent players operating in the gene therapy clinical trial services industry include:

Almac Group
Catalent Biologics
Charles River Laboratories International, Inc.
ICON plc
IQVIA Biotech
Labcorp Drug Development
Medpace Holdings, Inc.
Novotech
Parexel International (MA) Corporation
Precision Medicine Group LLC
Sharp Services, LLC
Thermo Fisher Scientific Inc.
Worldwide Clinical Trials

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The gene therapy clinical trial services market size was valued at USD 1.1 billion in 2023 and is estimated to grow at 9.2% CAGR from 2024 to 2032, attributed to the global rise in genetic disorders and chronic diseases.

The pharmaceutical & biotechnology companies end-use segment in the market may record USD 1.1 billion in revenue by 2032, due to their substantial R&D investments.

Asia Pacific gene therapy clinical trial services market size will grow at 9.6% CAGR between 2024 and 2032 due to increasing healthcare expenditure.

Almac Group, Catalent Biologics, Charles River Laboratories International, Inc., ICON plc, IQVIA Biotech, Labcorp Drug Development, Medpace Holdings, Inc., Novotech, and Parexel International (MA) Corporation among others.